摘要
目的探讨低分子肝素联合期待疗法治疗子痫前期的临床效果。方法选取在台前县人民医院2021年5月至2022年8月接受治疗的共计84例子痫前期患者,根据随机数字表法分为研究组(n=42)与对照组(n=42),对照组实行期待疗法,研究组实行低分子肝素联合期待疗法,对两组临床疗效、凝血功能、血压、24 h尿蛋白、不良事件、妊娠结局进行比较。结果研究组治疗有效率(95.24%)较对照组(78.57%)更高,差异有统计学意义(P<0.05);治疗后两组凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)、凝血酶时间(TT)延长,差异有统计学意义(P<0.05),纤维蛋白原(FIB)水平降低,差异有统计学意义(P<0.05),研究组PT、APTT、TT较对照组更长,FIB更低,差异有统计学意义(P<0.05);治疗后两组舒张压(DBP)、收缩压(SBP)、24 h尿蛋白定量降低,差异有统计学意义(P<0.05),研究组较对照组更低,差异有统计学意义(P<0.05);研究组不良事件发生率(4.76%)与对照组(21.43%)比较更低,差异有统计学意义(P<0.05);研究组不良妊娠结局发生率(4.76%)较对照组(23.38%)更低,差异有统计学意义(P<0.05)。结论低分子肝素联合期待疗法应用于子痫前期患者中,能够促进提高临床疗效,调节凝血功能,改善血压,减少不良事件及不良妊娠结局发生。
Objective To explore the clinical effect of low molecular weight heparin combined with expectant therapy in the treatment of preeclampsia.Methods A total of 84 patients with preeclampsia who were received treatment in our hospital from May 2021 to August 2022 were selected,anf randomly divided into the study group(n=42)and the control group(n=42).The control group received expectant therapy,while the research group received low-molecular-weight heparin combined with expectant therapy,The clinical efficacy,coagulation function,blood pressure,24-hour urine protein,adverse events,and pregnancy outcomes of the two groups were compared.Results In the total effective rate of treatment,in comparision of the control group(78.57%),the research group(95.24%)was higher,the difference was statistically significant(P<0.05).After treatment,the prothrombin time(PT),activated partial thromboplastin time(APTT),and thrombin time(TT)in both groups were prolonged,the difference was statistically significant(P<0.05),while the levels of FIB were reduced,the difference was statistically significant(P<0.05),in comparision of the control group,PT,APTT,and TT in the study group were longer(P<0.05),and FIB was lower,the difference was statistically significant(P<0.05).After treatment,DBP,SBP,and 24-hour urine protein quantification in both groups were decreased,the difference was statistically significant(P<0.05),and in comparision of the control group,the study group was lower,the difference was statistically significant(P<0.05).In the total incidence of adverse events,in comparision of the control group(21.43%),the study group(4.76%)was lower(P<0.05).In the total incidence of adverse pregnancy outcomes,in comparision of the control group(23.38%),the study group(4.76%)was lower,the difference was statistically significant(P<0.05).Conclusion The combination of low molecular weight heparin and expectant therapy can promote the improvement of clinical efficacy,regulate coagulation function,improve blood pressure,and reduce adverse events and pregnancy outcomes in patients with preeclampsia.
作者
薛秋玲
匡红丽
XUE Qiuling;KUANG Hongli(Obstetrics,Taiqian County People's Hospital,Puyang Henan 457600,China)
出处
《临床研究》
2023年第7期59-62,共4页
Clinical Research
关键词
低分子肝素
期待疗法
子痫前期
临床效果
low molecular weight heparin
expectant therapy
preeclampsia
clinical effects
